Insilico Medicine - 10 Years of AI Drug Discovery Innovation
Insilico Medicine was born at the Emerging Technology Centers in Baltimore in 2014 where founder and co-CEO Alex Zhavoronkov first began exploring combining bioinformatics with deep learning. He announced the company in 2015 at the NVIDIA GTC conference. The Company published our first proof-of-concept studies in 2016 in Nature Communications on a new method to uncover disease pathways using deep neural networks, the precursor of our powerful PandaOmics target discovery tool.
By 2019, we had published an experimental validation of our generative chemistry platform, Chemistry42, also in Nature, demonstrating that we could use our deep learning model to produce a de novo small molecule that was tested and validated in animal studies. We understood that we were onto something big – and we were determined to take our AI-developed drugs all the way to the clinic.
In 2021, Insilico brought on Dr. Feng Ren, Chief Scientific Officer, and co-CEO, to lead our clinical trial efforts, build a team of expert drug hunters, and take us to the finish line. Now, we have a lead AI-designed drug for idiopathic pulmonary fibrosis in Phase II trials with patients, five drugs at the clinical stage, and 31 drugs in our pipeline, including for cancer, fibrosis immunology, IBD, and COVID-19.
We’ve licensed a number of our therapeutic assets in strategic deals with Sanofi, Exelixis, MENARINI Group, Fosun Pharma and others. And we also license our AI platform software to many pharma and biotech companies and academic partners to enable faster global drug discovery and industry-scale validation.
Insilico Medicine is aligned over one mission: to develop very effective, very safe, life-saving therapeutics that target disease and aging simultaneously.
#ai #genai #drugdiscovery #anniversary #pharma #biotech #innovation #10years #clinicaltrials
Видео Insilico Medicine - 10 Years of AI Drug Discovery Innovation канала Insilico Medicine
By 2019, we had published an experimental validation of our generative chemistry platform, Chemistry42, also in Nature, demonstrating that we could use our deep learning model to produce a de novo small molecule that was tested and validated in animal studies. We understood that we were onto something big – and we were determined to take our AI-developed drugs all the way to the clinic.
In 2021, Insilico brought on Dr. Feng Ren, Chief Scientific Officer, and co-CEO, to lead our clinical trial efforts, build a team of expert drug hunters, and take us to the finish line. Now, we have a lead AI-designed drug for idiopathic pulmonary fibrosis in Phase II trials with patients, five drugs at the clinical stage, and 31 drugs in our pipeline, including for cancer, fibrosis immunology, IBD, and COVID-19.
We’ve licensed a number of our therapeutic assets in strategic deals with Sanofi, Exelixis, MENARINI Group, Fosun Pharma and others. And we also license our AI platform software to many pharma and biotech companies and academic partners to enable faster global drug discovery and industry-scale validation.
Insilico Medicine is aligned over one mission: to develop very effective, very safe, life-saving therapeutics that target disease and aging simultaneously.
#ai #genai #drugdiscovery #anniversary #pharma #biotech #innovation #10years #clinicaltrials
Видео Insilico Medicine - 10 Years of AI Drug Discovery Innovation канала Insilico Medicine
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Insilico Medicine: An Extraordinary JourneyIntroducing nach0: A one-stop LLM for chemical and biomedical tasksGenerative Adversarial Networks for Drug Discovery 4x3Insilico Announces Preclinical Candidate for Inhalable Formulation of Generative AI IPF DrugDecoding Cancer with AITour Insilico Medicine's AI-Powered Robotics LabIntroducing Docuthon - A Documentary Hackathon for AI Drug DiscoveryPharma.AI Launch, November 14 2022Precious3GPT - Multimodal Omics Transformer from Insilico MedicineKOLs' Interview Series: Dr. Yuan-Hua Ding, Founder & CEO at ATBLegends of Longevity Biotechnology - the 10th ARDD ConferenceInsilico Robotics Lab by The Afgan DreamersExploring the Future of Medicine-Docuthon WinnerNVIDIA founder and CEO Jensen Huang GTC Keynote on Generative AIPharma.AI - the platform for target discovery, drug design, and clinical trial predictionInClinico - a platform for clinical leaders to assess trial risk and aid in portfolio triage.A Prior of a Googol Gaussians a Tensor Ring Induced Prior for Generative ModelsFireside chat with Michael Levitt: acceleration of AI-powered drug discoveryKOLs' Interview Series: Dr. Yuri NikolskyTraining AI Robots with a Human CoachAnnouncing ChatPandaGPT - 1st Chat Functionality in AI Drug Discovery